Insider · CIK 0001198554
Bianco James A.
ceoofficerdirector
Files at HURA (Kintara Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 12, 2024 | HURA Kintara Therapeutics, Inc. | AGrant or award Options (Right to Buy)derivative | +1,065,990 | $0.00 | $0 | 1,065,990 | Nov 14, 2024 |
| Oct 18, 2024 | HURA Kintara Therapeutics, Inc. | AGrant or award Common Stock | +2,323,307 | $0.00 | $0 | 2,323,307 | Oct 22, 2024 |
| Oct 18, 2024 | HURA Kintara Therapeutics, Inc. | AGrant or award Options (Right to Buy)derivative | +357,800 | $0.00 | $0 | 357,800 | Oct 22, 2024 |
| Oct 18, 2024 | HURA Kintara Therapeutics, Inc. | AGrant or award Options (Right to Buy)derivative | +71,560 | $0.00 | $0 | 71,560 | Oct 22, 2024 |
| Oct 18, 2024 | HURA Kintara Therapeutics, Inc. | AGrant or award Options (Right to Buy)derivative | +191,280 | $0.00 | $0 | 191,280 | Oct 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.